ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,346.99
-0.11%
US Tech 100
18,488.00
-0.25%
다우존스 지수
38,798.99
-0.22%
Bitcoin
69,420.00
0.12%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Viking Therapeutics Inc (VKTX)

  7. Viking Therapeutics Inc (VKTX) 뉴스

VKTX

Viking Therapeutics (VKTX)

Viking Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:VKTX
일자시간출처헤드라인심볼기업
2024/06/0420:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
2024/06/0420:05PR Newswire (US)Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)NASDAQ:VKTXViking Therapeutics Inc
2024/05/3105:03PR Newswire (US)Viking Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:VKTXViking Therapeutics Inc
2024/05/2306:12Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:VKTXViking Therapeutics Inc
2024/05/2305:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VKTXViking Therapeutics Inc
2024/04/2505:05PR Newswire (US)Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
2024/04/2420:31IH Market NewsU.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures TradingNASDAQ:VKTXViking Therapeutics Inc
2024/04/1805:05PR Newswire (US)Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024NASDAQ:VKTXViking Therapeutics Inc
2024/03/2620:03PR Newswire (US)Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735NASDAQ:VKTXViking Therapeutics Inc
2024/03/0509:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/03/0509:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/03/0506:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
2024/03/0506:45PR Newswire (US)Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:VKTXViking Therapeutics Inc
2024/03/0206:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VKTXViking Therapeutics Inc
2024/02/2910:50PR Newswire (US)Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
2024/02/2807:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VKTXViking Therapeutics Inc
2024/02/2806:19PR Newswire (US)Viking Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:VKTXViking Therapeutics Inc
2024/02/2721:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
2024/02/2721:03PR Newswire (US)Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityNASDAQ:VKTXViking Therapeutics Inc
2024/02/1010:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/1006:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/0909:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/0909:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/0906:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/0906:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VKTXViking Therapeutics Inc
2024/02/0807:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VKTXViking Therapeutics Inc
2024/02/0807:24Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VKTXViking Therapeutics Inc
2024/02/0806:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VKTXViking Therapeutics Inc
2024/02/0806:05PR Newswire (US)Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:VKTXViking Therapeutics Inc
2024/02/0110:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VKTXViking Therapeutics Inc
 검색 관련기사 보기:NASDAQ:VKTX

최근 히스토리

USOTC
BASFY
BASF (QX)
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
GOOGL
Alphabet
NYSE
NKE
Nike
NYSE
DIS
Walt Disney
NYSE
AXP
American Express
NYSE
MRK
Merck
AMEX
SPY
SPDR S&P 500
NYSE
MCD
McDonalds
COIN
BTCUSD
Bitcoin
FX
USDEUR
US Dollar vs Euro
NASDAQ
NVDA
NVIDIA
NASDAQ
AAPL
Apple
USI
USTECH100
US Tech 100
PM
XAUUSD
Gold vs US Dollar
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유